FS Bancorp, Inc. (FSBW)
Live price chart, market sentiment, and community perspectives for FS Bancorp, Inc. (NASDAQ: FSBW).
Live price chart, market sentiment, and community perspectives for FS Bancorp, Inc. (NASDAQ: FSBW).
On our desk, looking at FSBW trading around $42.63 with a P/E near 9.74, the valuation looks compressed but fair given the recent Q2 EPS miss. Even though earnings per share came in at $1.04 versus expectations around $1.10, the stock barely flinched and ticked up slightly. That resilience suggests the market is already pricing in steady performance and looking past the near-term miss, likely keeping an eye on the broader regional banking context.
As a hedge fund PM reviewing alternative data signals, AltIndex's score of 52/100 'Hold' aligns well with our internal models. While employee business outlook sentiment sits at a healthy 79% positive, top-line revenue metrics and fundamental scores lagging in the 38-to-41 range tell us to remain patient. We are maintaining a neutral stance until integration updates on the Pacific West transaction become clearer.
From a risk management standpoint, the pending merger agreement where Pacific West Bancorp merges into FS Bancorp adds an interesting structural catalyst. With FSBW declaring its 54th consecutive quarterly cash dividend and showing sequential net income growth up to $7.9 million for Q2 2026, the fundamental floor feels protected, though the 52-week range ceiling near $45.85 caps immediate explosive upside.
From a quantitative perspective, the consensus analyst rating breakdown showing 1 sell, 2 holds, and 1 buy with a $45.00 target implies minimal forecasted upside of roughly 4.6% from current levels. Given the low trading volume velocity and 11.0% ROE, we aren't seeing enough short-term momentum to justify aggressive directional positioning without a broader sector rotation into regional banks.
On the options desk, implied volatility for FSBW remains subdued, reflecting the neutral 50% positive and 50% neutral/negative sentiment split across public forums. With a trailing twelve-month EPS of $4.29 and a modest 3.2% dividend yield, the equity functions more as an income vehicle than a high-beta growth play, making out-of-the-money options strategies less attractive right now.
Explore plasma cleansing, somatic organ swaps, and BCI.